---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-082641"
form_type: "8-K"
ticker: "KYMR"
cik: "0001815442"
company_name: "Kymera Therapeutics, Inc."
filed_at: "2024-04-01T23:59:59+00:00"
generated_at: "2026-06-04T04:49:38.630365+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Kymera appoints Felix J. Baker as director and Lead Independent Director

## Summary
- Felix J. Baker appointed to Board as Class II director effective March 28, 2024; also named Lead Independent Director.
- Dr. Baker is managing member of Baker Bros. Advisors LP, which is affiliated with shareholders holding >5% of stock.
- Baker affiliates purchased 4,950,495 pre-funded warrants at $25.2499 each in January 2024; Dr. Baker deemed beneficial owner.
- Compensation: option to purchase 32,000 shares at closing price on March 28, vesting over 3 years; annual retainer $60,000 as Lead Independent Director.
- Board determined Dr. Baker independent under Nasdaq standards; committee assignments pending.

## SEC filing metadata
- accession: 0001193125-24-082641
- form_type: 8-K
- ticker: KYMR
- cik: 0001815442
- company_name: Kymera Therapeutics, Inc.
- filed_at: 2024-04-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815442/000119312524082641/0001193125-24-082641-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815442/000119312524082641/d812269d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-082641
- JSON: https://secwatch.observer/filing/0001193125-24-082641.json
- Plain text: https://secwatch.observer/filing/0001193125-24-082641.txt

## Key facts
- Executive change
  Felix J. Baker was appointed as Director and Lead Independent Director at Kymera Therapeutics, Inc..
  - Action: appointed
  - Role: Director and Lead Independent Director
  source text: On March 28, 2024, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Kymera Therapeutics, Inc. (the “Company”), the Board appointed Felix J. Baker, Ph.D. to join the Board, effective March 28, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815442/000119312524082641/0001193125-24-082641-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.